IM8 hits $200M ARR in 18 months with David Beckham and a $1B General Catalyst growth commitment

IM8 hits $200M ARR in 18 months with David Beckham and a $1B General Catalyst commitment

Danny Yeung, CEO of Prenetics, co-founded IM8 with David Beckham 19 months ago. The supplement brand hit $100M ARR within 11 months and $200M ARR within 18 months — Yeung claims it's the fastest-growing supplement brand ever recorded in the industry, where reaching $100M typically takes three to five years.

The growth outpaced its own model by a wide margin. The initial full-year revenue target was $30M. They did $60M. This year, Yeung expects well over $200M.

“We hit a 100,000,000 ARR within eleven months. We hit 200,000,000 ARR within eighteen months... iMATE is actually part of a public listed company, Prenetics, listed on the NASDAQ under the stock ticker PRE. And then so with that, we've gotten a $1,000,000,000 growth commitment from General Catalyst.”

Global from day one

Where most US direct-to-consumer brands wait years before going international, IM8 launched in 31 countries on day one, with the US, Canada, UK, Australia, and Singapore as its top five markets. It now ships to 43 countries and delivers 200,000 servings daily, with 52 million servings delivered across the 19-month period.

Beckham's global profile is the obvious structural advantage — it compresses the brand-building timeline that would otherwise take years of market-by-market expansion.

The $1B General Catalyst commitment

IM8 sits inside Prenetics, a Nasdaq-listed company trading under the ticker PRE. General Catalyst committed $1B through its Customer Value Fund, a financing structure it has previously used with Lemonade and Grammarly. The model works by underwriting predictable future revenue based on retention cohort data: for every dollar IM8 spends on marketing, General Catalyst fronts 70 cents, which Prenetics repays from gross profits over roughly two to three months at an interest rate of approximately 3.5% for payback periods under three months.

It is revenue-based financing, not equity. General Catalyst is taking a bet on the durability of IM8's customer cohorts, not its valuation.

The public market disconnect

Prenetics's current market cap sits at roughly $354M, against a business projecting $200M+ in revenue this year and holding approximately $140M in cash even before the General Catalyst facility. Yeung attributes the gap partly to legacy perception — Prenetics scaled rapidly on COVID-era PCR testing (40,000 tests per day at its peak) and the market hasn't fully repriced the company around its new core business. Whether the public markets close that gap depends on whether IM8's retention data continues to support the growth trajectory General Catalyst is now financing.